GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells

Document Type

Article

Publication Date

8-20-2025

Publication Title

Sci Rep

Abstract

Metabolic reprogramming is recognized as a hallmark of cancer frequently associated with drug resistance in ovarian cancer. This is problematic as ovarian cancer is one of the deadliest gynecologic cancers with platinum resistance contributing to poor survival. However, the mechanism by which ovarian cancer cell metabolism contributes to platinum resistance is not well understood. Herein, metabolic signatures were determined in platinum-resistant ovarian cancer cell lines compared to the more platinum-sensitive parental lines. Chemoresistant ovarian cancer cells showed increased oxidative phosphorylation (OXPHOS) compared to chemosensitive cells. This was associated with elevated levels of glutaminolysis and tricarboxylic acid (TCA)-related metabolites supporting their dependence on OXPHOS. Key enzymes involved in glutaminolysis, specifically, glutamic-pyruvic transaminase 2 (GPT2), were upregulated in chemoresistant compared to chemosensitive cells. Interestingly, high GPT2 gene expression is associated with worse prognosis in ovarian cancer patients, adding translational relevance to the pre-clinical findings. GPT2 knockout in chemoresistant cells restored the metabolic phenotype to that of the sensitive cells and reversed drug resistance. These data suggest that GPT2 is a critical link between glutaminolysis, the TCA cycle, and OXPHOS and is a potential target to attenuate the increased metabolic activity associated with a chemoresistant phenotype.

Medical Subject Headings

Humans; Female; Drug Resistance; Neoplasm; Glutamine; Ovarian Neoplasms; Cell Line; Tumor; Transaminases; Oxidative Phosphorylation; Citric Acid Cycle; Gene Expression Regulation; Neoplastic; Platinum; Antineoplastic Agents

PubMed ID

40835655

Volume

15

Issue

1

First Page

30528

Last Page

30528

Find It @ Sladen

Share

COinS